What SELECT changed about how semaglutide is discussed, and what it did not posts 121–133

Injection site does not appear to matter much for semaglutide exposure. The published comparisons of abdomen, thigh and upper arm found differences small enough to be clinically unimportant, which is not true of every injectable.

On reflection I would soften that slightly.

I would call the community position on SELECT likely rather than established, and I would be comfortable defending that hedge.

Coming back to post #121, because the follow-up matters more than the original answer.

SELECT is a question about a distribution, not about a value, and treating it as a value is what produces the confident wrong answers.

Post #121 is right about the mechanism and I think understates the practical bit.

Semaglutide versus liraglutide in STEP 8: semaglutide produced greater weight reduction and the discontinuation rates differed. But the trial was open-label for the dosing schedule, which admits expectation effects. Weekly versus daily itself is part of the comparison, not a confounding variable to be removed.

The opalescent appearance in semaglutide solutions is occasionally noted and the mechanism is unclear. It does not appear to correlate with product failure in practice. Visible particles or frank cloudiness is different and would be reason to contact the supplier.

The interesting part of this is the exception, and I do not understand the exception.

Agreed on all of that, and I have nothing to add to it.

I read post #125 twice before replying, because I had assumed the opposite.

What I can speak to on SELECT is narrow, so I will keep it narrow rather than generalising from it. Beyond that boundary I do not know.

Summarising the SELECT thread so far, since it is long and the answer is buried: the first reply has the method, the fourth has the correction to it, and the rest is people agreeing at length.

Post #125 put the caveat in the right place and I want to underline it.

The 2.4 mg maintenance dose in the weight-management programme and the 1.0 mg diabetes dose are frequently discussed as though they were the same drug at different strengths. They are, but the trials behind them enrolled different populations for different endpoints, so the evidence does not transfer sideways.

Building on post #129 rather than restating it.

On alcohol: the labelling does not contraindicate it, but it raises gastric irritation risk and semaglutide already does that. There is no published interaction study and the conservative position is to limit it if you are titrating or if gastrointestinal symptoms are troublesome.

Adding the measurement that post #128 says would settle it.

Filing a mild objection to the consensus on SELECT. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit.

Post #130 describes the usual case. This is about the unusual one.

On the injection-day question: the labelling for licensed semaglutide allows the day to be changed provided at least two days separate the two injections. That interval is not arbitrary — it is what stops two doses stacking inside one absorption window.

Adding this to the thread rather than to the wiki, because I am not confident enough for the wiki.

Semaglutide's structure is a modified backbone with a C18 diacid attached through a spacer. The acylation is the reason for the long half-life and it is also the reason a plain sequence comparison against native GLP-1 is misleading about how the molecule behaves.